Equities

Matricelf Ltd

MTLF:TLV

Matricelf Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ILa)397.10
  • Today's Change7.10 / 1.82%
  • Shares traded10.05k
  • 1 Year change-12.42%
  • Beta1.5535
Data delayed at least 20 minutes, as of Nov 21 2024 15:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

  • Revenue in ILS (TTM)0.00
  • Net income in ILS-13.66m
  • Incorporated2019
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Purple Biotech Ltd0.00-59.39m17.86m20.00--0.1412-----0.2169-0.21690.000.34460.00----0.00-38.33-37.24-44.43-41.28-------9,415.70----0.0088------8.25---28.45--
Nextage Therapeutics Ltd1.02m-3.36m27.56m--------26.97-0.1057-0.10570.032-0.12931.58--10.32---553.86-188.94---423.7622.6033.33-351.17-2,486.19---65.46------17.9930.57------
Kadimastem Ltd0.00-9.68m53.30m32.00---------2.12-2.120.00-1.940.00-------129.59-155.33---1,831.12-----------3.113.31------47.14---50.73--
Matricelf Ltd0.00-13.66m63.81m----2.96-----0.8738-0.87380.001.340.00-------47.15---50.89--------------0.057-------10.77------
X T L Biopharmaceuticals Ltd1.68m-83.31m80.94m33.00--0.4222--48.13-0.3783-0.37830.00760.15280.0192--0.701250,963.56-94.96-53.17-111.98-59.10---2.33-4,953.75-1,084.42----0.00---85.80---7.97---53.12--
DNA Group TR Ltd306.00k15.05m110.60m14.007.351.13--361.440.12220.12220.00250.79810.0033--1.4421,857.1416.35-23.5416.48-26.27----4,918.63-7,406.24----0.00---45.36--95.00------
BioLine RX Ltd43.17m-182.06m127.45m79.00--2.39--2.95-0.1884-0.18840.0430.04450.1939--6.40546,516.30-81.75-52.74-127.94-65.4355.84---421.69-3,501.791.05-519.430.4642-------142.93---50.72--
Bonus Biogroup Ltd0.00-29.19m134.31m58.00--8.72-----0.0718-0.07180.000.01320.00----0.00-64.14-76.10-74.97-97.19------------0.4106------26.29--19.30--
Data as of Nov 21 2024. Currency figures normalised to Matricelf Ltd's reporting currency: Israeli Shekel ILS

Institutional shareholders

0.37%Per cent of shares held by top holders
HolderShares% Held
Meitav Mutual Funds Ltd.as of 31 Jul 202426.42k0.16%
KSM Mutual Funds Ltd.as of 31 Jul 202421.49k0.13%
Migdal Mutual Funds Ltd.as of 31 Jul 20248.88k0.06%
Psagot Mutual Funds Ltd.as of 31 Jul 20242.51k0.02%
Harel Mutual Funds Ltd.as of 31 Jul 2024891.000.01%
More ▼
Data from 31 Jul 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.